Acadia Q2 2026: Cash Flow Keeps the Pace as GAAP EPS Dips, Beds Grow

Overview: A cash-flow story with a one-off earnings drag

Acadia reported a second quarter that looked, on the surface, like a steady drumbeat: revenue of $865.8 million — essentially flat versus the prior-year quarter. After normalization for the Florida supplement payment program revenue in each quarter, the growth rate stood at about 2.8%. The core operating environment was stable but not spectacular: same-facility revenue was flat as patient days rose 0.8% while revenue per patient day declined 0.8%. In the language of Wall Street, the top line is fine; the big questions sit in the bottom line and the cash flow engine.

The EPS story, however, is more mixed. GAAP net income attributable to Acadia came in at $10.9 million, or $0.12 per diluted share, versus $30.1 million, or $0.33 per diluted share, in the prior-year period. On the non-GAAP side, adjusted net income was $35.1 million, or $0.38 per diluted share, down from $74.8 million, or $0.83 per diluted share, in the prior year. The delta reflects a few moving parts: a $28.6 million adjustment to professional and general liability reserves (PLGL) that weighs on EBITDA, partially offset by a $26.1 million benefit tied to the Florida supplemental payment program and provider tax adjustments.

On the liquidity and cash-flow front, operating cash flows were $162.1 million, up from $133.5 million a year ago, while capital expenditures were $38.6 million versus $167.7 million in the prior year. And the company added 240 licensed beds during the quarter, signaling ongoing capacity expansion as demand for behavioral health services remains robust in various markets.

Key metrics at a glance

• Revenue: $865.8 million (roughly flat YoY); revenue forecast implications for the second half remain a focal point for investors.
• GAAP EPS: $0.12 per share; earnings surprise expectations will hinge on how consensus compares to this figure.
• Adjusted EPS: $0.38 per diluted share; prior-year: $0.83.
• Adjusted EBITDA: $149.2 million; includes a $28.6 million PLGL reserve charge and a $26.1 million Florida program benefit.
• Net income (GAAP): $10.9 million.
• Operating cash flow: $162.1 million; capex $38.6 million.
• Beds added: 240 licensed beds in the quarter.
• Guidance: Updated full-year 2026 financial and cash flow guidance.

What this portends for Acadia and the sector

The raw GAAP numbers tell a story of a business navigating a mix of ongoing demand and one-off accounting items. The decline in EPS on a GAAP basis versus the prior year isn’t a surprise given the PLGL reserve adjustment and the Florida program offsets that show up in the adjustments. The EPS consensus landscape will matter here: analysts will reconcile the GAAP EPS with adjusted figures and the non-cash or one-time items to gauge the ongoing earning power of Acadia’s core operations.

What stands out, beyond the headline EPS, is the cash-flow resilience. A leap in operating cash flow to $162.1 million and a sharp drop in capex to $38.6 million imply the company is extracting more free cash flow from its existing footprint even as it continues to deploy capital toward capacity expansion (240 beds added this quarter). In a sector where occupancy ramp and patient mix can swing results, Acadia’s ability to convert operating cash flow into capital-light expansion or debt reduction could be a differentiator in the back half of 2026.

The Florida supplemental payment program and provider tax adjustments illustrate a recurring dynamic in healthcare: regulatory and payer programs move the levers on reported earnings, sometimes more than the patient day metrics do. If those benefits persist, Adjusted EBITDA and adjusted earnings will tell a more favorable story than the GAAP line suggests. If the headwinds reassert, the stock’s reaction will likely hinge on whether investors view those adjustments as temporary or structural.

Strategically, Acadia’s path aligns with a broader trend in behavioral health: disciplined operational execution, selective capex, and growth through openings with JV partners. The two new facilities with JV partners hint at a model that manages capital velocity while sharing risk. For sector peers, the quarter signals that investors reward cash generation and capacity expansion that appears scalable, even when GAAP earnings are under pressure from non-operational items.

Guidance and the road ahead

The company issued updates to its full-year 2026 financial and cash-flow guidance. While the press release excerpt here doesn’t lay out specific numeric targets, the combination of stronger cash flow, ongoing capacity additions, and a managed one-time charge structure suggests that Acadia is aiming to sustain a robust cash-generation profile even as GAAP earnings take a temporary back seat. For investors, the key will be how the revenue forecast and adjusted metrics evolve as Florida-related effects normalize and occupancy in newly opened facilities matures.

From a sector perspective, the message is relevant. When a player like Acadia emphasizes free cash flow, EBITDA quality, and capacity expansion amid a modest top-line arc, peers in the behavioral-health space may recalibrate expectations around roll-out pace, capital discipline, and how much wiggle room exists in non-operating adjustments to protect earnings quality.

From leadership

“Acadia delivered solid results in the second quarter that were driven by our continued focus on disciplined operational execution and providing quality care for our patients,” said Debbie Osteen, Chief Executive Officer. The message: progress is real where it matters—occupancy, cash flow, and patient access—while the financials continue to reflect both ongoing operational realities and regulatory quirks that require careful interpretation by investors and analysts alike.

Bottom line

Acadia’s Q2 2026 results underscore a familiar pattern in healthcare services: robust cash generation and capacity expansion can coexist with GAAP earnings that carry one-off adjustments and regulatory timing effects. For ACHC, the bar to watch will be whether the revenue forecast for the second half of 2026, the trajectory of EPS (both GAAP and adjusted), and the sustainability of adjusted EBITDA gains outpace any headwinds from payer mix or regulatory shifts. If the company can translate the bed additions and JV partnerships into consistent occupancy and patient-day economics, the stock could start to look less like a windfall of one-time items and more like a sustainable growth engine within the sector.

In short, the quarter offers a quiet but meaningful reminder: in healthcare services, the distribution of cash and capacity often speaks louder than the quarterly echo of GAAP earnings. The coming quarters will reveal whether Acadia’s cash engine can power a steadier pace of growth across the broader behavioral-health peer group.